GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should Know

Zacks Equity Research - finance.yahoo.com Posted 5 years ago
image
GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $170.27, moving +1.28% from the previous trading session.
More

GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $170.27, moving +1.28% from the previous trading session. This change outpaced the S&P 500's 0.29% loss on the day. At the same time, the Dow lost 0.55%, and the tech-heavy Nasdaq gained 0.07%.

Prior to today's trading, shares of the company had gained 11.95% over the past month. This has outpaced the Medical sector's gain of 2.03% and the S&P 500's gain of 2.14% in that time.

Investors will be hoping for strength from GWPH as it approaches its next earnings release. The company is expected to report EPS of -$2.42, up 22.44% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $23.19 million, up 592.18% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$8.66 per share and revenue of $132.12 million, which would represent changes of +17.99% and +679.18%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 14.92% higher within the past month. GWPH is currently a Zacks Rank #2 (Buy).

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GW Pharmaceuticals PLC (GWPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.